Unresectable hepatocellular carcinoma (HCC)
Conditions
Interventions
The observation group of inoperable liver cancer:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis criteria: Hepatocellular carcinoma (HCC) confirmed by histopathology or dynamic enhanced CT/MRI (meeting LI-RADS 5-class criteria); 2. Disease stage: Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate) or stage C (advanced); 3. Inoperability: Confirmed by the multidisciplinary team (MDT) assessment as being unable to undergo surgical resection (based on at least one of the following): · Tumor location invading important blood vessels (main portal vein/portal vein tumor thrombus) · Multiple tumors (>=4) or diffuse liver cancer · Residual liver volume < 30% or insufficient liver function reserve 4. Treatment history: During the period from January 2015 to December 2020, received: · Experimental group: At least 2 cycles of TACE-HAIC combined treatment (TACE: cTACE or D-TACE; HAIC: FOLFOX or RALOX regimen) · Control group: At least 2 cycles of single TACE treatment (cTACE or D-TACE) 5. Liver function: Child-Pugh grade A or B (total score <= 9); 6. Physical condition: ECOG score 0-2; 7. Complete baseline data: Possess complete baseline imaging (enhanced CT/MRI), laboratory tests (AFP, liver function, blood routine), and treatment records.
Exclusion criteria
Exclusion criteria: 1. Mixed pathological types: - Mixed hepatocellular carcinoma (with cholangiocarcinoma components) - Metastatic hepatocellular carcinoma or extrhepatic primary malignant tumors 2. Severe organ dysfunction: - Liver function at Child-Pugh C grade (total score >= 10 points) - Renal insufficiency (eGFR 2000 IU/ml without antiviral treatment) - Complete occlusion of the main portal vein with extensive collateral circulation - Coagulation dysfunction (INR > 1.5 and uncorrectable) 5. Missing key data: - Incomplete records of survival status or treatment details - Unavailable baseline imaging data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS);Objective Response Rate;Disease Control Rate (DCR); | — |
Countries
China
Contacts
Public ContactChang Liu
West China Hospital of Sichuan University
Outcome results
None listed